Ipca Laboratories
Ipca Laboratories Limited, headquartered in Mumbai, India, is a prominent player in the pharmaceutical industry, specialising in the manufacture and export of active pharmaceutical ingredients (APIs) and finished dosage forms. Founded in 1949, the company has achieved significant milestones, including a robust presence in over 100 countries and a diverse product portfolio that encompasses a wide range of therapeutic areas such as cardiovascular, anti-infective, and pain management. With a commitment to quality and innovation, Ipca Laboratories stands out for its extensive range of generic formulations and APIs, which are produced in state-of-the-art facilities adhering to international standards. The company has garnered a strong market position, recognised for its consistent growth and contributions to healthcare, making it a trusted name in the global pharmaceutical landscape.
DitchCarbon Score
How does Ipca Laboratories's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ipca Laboratories's score of 21 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ipca Laboratories's reported carbon emissions
In 2024, Ipca Laboratories reported total carbon emissions of approximately 311,883,000 kg CO2e. This figure reflects a significant reduction from 2022, when emissions were about 326,556,000 kg CO2e. The emissions for 2023 were broken down into Scope 1 and Scope 2, with Scope 1 emissions at approximately 174,538,000 kg CO2e and Scope 2 emissions at about 137,345,000 kg CO2e. Ipca Laboratories has set ambitious climate commitments, aiming for a 20% reduction in carbon emissions across both Scope 1 and Scope 2 by 2030, with the baseline year being 2022. This target underscores their commitment to sustainability and aligns with industry standards for climate action. The company has disclosed emission intensity metrics, including an emission intensity of approximately 32,100 kg CO2e per tonne for Active Pharmaceutical Ingredients (API) and 0.05627 kg CO2e per unit of revenue in INR for pharmaceutical sites, indicating a focus on improving efficiency in their operations. Overall, Ipca Laboratories is actively working towards reducing its carbon footprint while maintaining transparency in its emissions reporting and climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 124,880,000 | 000,000,000 |
| Scope 2 | 179,114,000 | 000,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ipca Laboratories is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
